 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- JNJ-63682918 / J&J, Bavarian Nordic, JNJ-63682931 / Bavarian Nordic, J&J, JNJ-65195208 / J&J
Trial completion date, Trial termination: Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - Dec 17, 2020
P1/2, N=9, Terminated, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Dec 2022 --> Oct 2020 | Active, not recruiting --> Terminated; Low enrolment and increasing COVID restrictions, following an earlier enrolment pause in April made it clear that completion of the study would not be feasible
- ||| JNJ-63682918 / J&J, Bavarian Nordic, JNJ-63682931 / Bavarian Nordic, J&J, JNJ-65195208 / J&J
Enrollment closed, Enrollment change: Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - Sep 22, 2020
P1/2, N=10, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Dec 2022 --> Oct 2020 | Active, not recruiting --> Terminated; Low enrolment and increasing COVID restrictions, following an earlier enrolment pause in April made it clear that completion of the study would not be feasible Recruiting --> Active, not recruiting | N=66 --> 10
- | JNJ-63682918 / J&J, Bavarian Nordic, JNJ-63682931 / Bavarian Nordic, J&J, JNJ-65195208 / J&J
Trial completion date: Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - Mar 18, 2020
P1/2, N=66, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting | N=66 --> 10 Trial completion date: Sep 2022 --> Dec 2022
- | JNJ-63682918 / J&J, Bavarian Nordic, JNJ-63682931 / Bavarian Nordic, J&J, JNJ-65195208 / J&J
Trial completion date: Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - Nov 11, 2019
P1/2, N=66, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Sep 2022 --> Dec 2022 Trial completion date: Apr 2021 --> Sep 2022
- | JNJ-63682918 / J&J, Bavarian Nordic, JNJ-63682931 / Bavarian Nordic, J&J, JNJ-65195208 / J&J
Trial completion date: Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - Mar 20, 2019
P1/2, N=66, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Apr 2021 --> Sep 2022 Trial completion date: Sep 2020 --> Mar 2021
- ||| JNJ-63682918 / J&J, Bavarian Nordic, JNJ-63682931 / Bavarian Nordic, J&J, JNJ-65195208 / J&J
Enrollment open: Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - Oct 11, 2018
P1/2, N=66, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Sep 2020 --> Mar 2021 Not yet recruiting --> Recruiting
- |||| JNJ-63682918 / J&J, Bavarian Nordic, JNJ-63682931 / Bavarian Nordic, J&J, JNJ-65195208 / J&J
New P1/2 trial: Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - Aug 1, 2018
P1/2, N=66, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.